{"id":"https://openalex.org/W1965730366","doi":"https://doi.org/10.3109/09546634.2015.1027167","title":"Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic","display_name":"Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic","publication_year":2015,"publication_date":"2015-04-17","ids":{"openalex":"https://openalex.org/W1965730366","doi":"https://doi.org/10.3109/09546634.2015.1027167","mag":"1965730366","pmid":"https://pubmed.ncbi.nlm.nih.gov/25886082"},"language":"en","primary_location":{"id":"doi:10.3109/09546634.2015.1027167","doi":"https://doi.org/10.3109/09546634.2015.1027167","is_oa":false,"landing_page_url":"https://doi.org/10.3109/09546634.2015.1027167","pdf_url":null,"source":{"id":"https://openalex.org/S21432770","display_name":"Journal of Dermatological Treatment","issn_l":"0954-6634","issn":["0954-6634","1471-1753"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Dermatological Treatment","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Eric Sorenson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Eric Sorenson","raw_affiliation_strings":["Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA and","institution_ids":["https://openalex.org/I1174212"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102727788","display_name":"John Y. M. Koo","orcid":"https://orcid.org/0009-0004-1005-5221","observed_orcids":["https://orcid.org/0009-0004-1005-5221"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Koo","raw_affiliation_strings":["Department of Dermatology, University of California San Francisco Psoriasis Treatment Center, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, University of California San Francisco Psoriasis Treatment Center, San Francisco, CA, USA","institution_ids":["https://openalex.org/I180670191"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1174212"],"apc_list":null,"apc_paid":null,"fwci":0.7239,"has_fulltext":false,"cited_by_count":32,"citation_normalized_percentile":{"value":0.60746339,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"26","issue":"6","first_page":"493","last_page":"501"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/biologic-agents","display_name":"biologic agents","score":0.8050000071525574},{"id":"https://openalex.org/keywords/plaque-psoriasis","display_name":"plaque psoriasis","score":0.9229999780654907},{"id":"https://openalex.org/keywords/etanercept","display_name":"etanercept","score":0.9300000071525574},{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":1.0},{"id":"https://openalex.org/keywords/ustekinumab","display_name":"ustekinumab","score":1.0},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7409999966621399},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7639999985694885},{"id":"https://openalex.org/keywords/squamous-cell-carcinoma","display_name":"squamous cell carcinoma","score":0.9380000233650208},{"id":"https://openalex.org/keywords/non-melanoma-skin-cancer","display_name":"non-melanoma skin cancer","score":0.9440000057220459},{"id":"https://openalex.org/keywords/injection-site-reactions","display_name":"injection site reactions","score":0.9369999766349792},{"id":"https://openalex.org/keywords/headache","display_name":"headache","score":0.7329999804496765},{"id":"https://openalex.org/keywords/upper-respiratory-tract-infection","display_name":"upper respiratory tract infection","score":0.9120000004768372},{"id":"https://openalex.org/keywords/moderate-to-severe-psoriasis","display_name":"moderate-to-severe psoriasis","score":0.777999997138977}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.954131543636322},{"id":"https://openalex.org/C2778975655","wikidata":"https://www.wikidata.org/wiki/Q420305","display_name":"Ustekinumab","level":4,"score":0.9230720400810242},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.8113675117492676},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7674843072891235},{"id":"https://openalex.org/C2777226972","wikidata":"https://www.wikidata.org/wiki/Q415343","display_name":"Etanercept","level":3,"score":0.7531832456588745},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.7428035736083984},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.5682487487792969},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.507731556892395},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4789774417877197},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41646426916122437},{"id":"https://openalex.org/C2776478404","wikidata":"https://www.wikidata.org/wiki/Q1105187","display_name":"Cochrane Library","level":3,"score":0.41251885890960693},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.3639270067214966},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.1738492250442505},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068800","descriptor_name":"Etanercept","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000068800","descriptor_name":"Etanercept","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000068879","descriptor_name":"Adalimumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000068879","descriptor_name":"Adalimumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000069549","descriptor_name":"Ustekinumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000069549","descriptor_name":"Ustekinumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001685","descriptor_name":"Biological Factors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001685","descriptor_name":"Biological Factors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.3109/09546634.2015.1027167","doi":"https://doi.org/10.3109/09546634.2015.1027167","is_oa":false,"landing_page_url":"https://doi.org/10.3109/09546634.2015.1027167","pdf_url":null,"source":{"id":"https://openalex.org/S21432770","display_name":"Journal of Dermatological Treatment","issn_l":"0954-6634","issn":["0954-6634","1471-1753"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Dermatological Treatment","raw_type":"journal-article"},{"id":"pmid:25886082","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25886082","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of dermatological treatment","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8500000238418579,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":47,"referenced_works":["https://openalex.org/W46529611","https://openalex.org/W83713607","https://openalex.org/W1500119734","https://openalex.org/W1541270304","https://openalex.org/W1608678290","https://openalex.org/W1661616496","https://openalex.org/W1751814457","https://openalex.org/W1909750378","https://openalex.org/W1943930704","https://openalex.org/W1964184432","https://openalex.org/W1975162362","https://openalex.org/W1981432623","https://openalex.org/W1989167852","https://openalex.org/W1989702104","https://openalex.org/W2005176759","https://openalex.org/W2008223306","https://openalex.org/W2008635283","https://openalex.org/W2008716526","https://openalex.org/W2012715950","https://openalex.org/W2016834798","https://openalex.org/W2022665587","https://openalex.org/W2023039127","https://openalex.org/W2050104340","https://openalex.org/W2056361036","https://openalex.org/W2058547807","https://openalex.org/W2063627867","https://openalex.org/W2070353058","https://openalex.org/W2071343804","https://openalex.org/W2080772504","https://openalex.org/W2082622860","https://openalex.org/W2085947993","https://openalex.org/W2088155036","https://openalex.org/W2091442391","https://openalex.org/W2103120331","https://openalex.org/W2111247729","https://openalex.org/W2116048670","https://openalex.org/W2116956799","https://openalex.org/W2122316162","https://openalex.org/W2126689331","https://openalex.org/W2126798127","https://openalex.org/W2131430597","https://openalex.org/W2133633410","https://openalex.org/W2146843653","https://openalex.org/W2163232748","https://openalex.org/W2164533070","https://openalex.org/W2168911501","https://openalex.org/W4248269869"],"related_works":["https://openalex.org/W2415742554","https://openalex.org/W3117839071","https://openalex.org/W4400221849","https://openalex.org/W125640847","https://openalex.org/W2093204464","https://openalex.org/W2981830759","https://openalex.org/W2141511729","https://openalex.org/W2981603084","https://openalex.org/W2119836161","https://openalex.org/W2290435082"],"abstract_inverted_index":{"BACKGROUND:":[0],"Biologic":[1],"agents":[2,19,185],"have":[3,20,29,190],"greatly":[4],"enhanced":[5],"the":[6,15,35,44,55,63,78,98,106,183],"treatment":[7,64,107],"of":[8,14,17,57,65,74,93,100,108,182,199],"moderate-to-severe":[9,66,109],"plaque":[10,67,110,177],"psoriasis.":[11,68,111],"Previous":[12],"reviews":[13],"safety":[16],"biologic":[18,184],"included":[21,132],"patients":[22,175],"with":[23,54,97,142,156,165,176],"conditions":[24],"other":[25],"than":[26],"psoriasis":[27],"and/or":[28],"not":[30],"used":[31],"statistical":[32,91,192,200],"significance":[33,201],"as":[34],"primary":[36],"analytic":[37],"focus.":[38],"Our":[39],"aim":[40],"was":[41],"to":[42,47,81,128],"review":[43],"current":[45],"literature":[46],"identify":[48,82],"significantly":[49,130,160],"increased":[50,131,161],"adverse":[51,94,162,180],"events":[52,95,126,163],"associated":[53,96,141,155,164],"use":[56,99],"etanercept,":[58,101,143,186],"adlimumab":[59,102],"and":[60,77,88,103,122,139,150,158,188],"ustekinumab":[61,104,189],"for":[62,105],"METHODS:":[69],"We":[70,113],"performed":[71],"a":[72],"search":[73],"Ovid":[75],"MEDLINE":[76],"Cochrane":[79],"Library":[80],"clinical":[83,116],"trials,":[84,117],"open-label":[85,119],"extension":[86,120],"studies":[87,121,196],"meta-analyses":[89],"reporting":[90],"analysis":[92,198],"RESULTS:":[112],"identified":[114],"17":[115],"2":[118],"8":[123],"meta-analyses.":[124],"Adverse":[125],"reported":[127],"be":[129,203],"squamous":[133],"cell":[134],"carcinoma":[135],"(SCC),":[136],"injection-site":[137],"reaction,":[138],"headache":[140],"overall":[144],"nonmelanoma":[145],"skin":[146],"cancer":[147],"(NMSC),":[148],"SCC,":[149],"upper":[151],"respiratory":[152],"tract":[153],"infection":[154],"adalimumab,":[157],"no":[159],"ustekinumab.":[166],"CONCLUSION:":[167],"Current":[168],"evidence":[169],"suggests":[170],"that":[171],"when":[172],"analyzed":[173],"among":[174],"psoriasis,":[178],"few":[179],"effects":[181],"adalimumab":[187],"reached":[191],"significance.":[193],"Further":[194],"long-term":[195],"conducting":[197],"should":[202],"performed.":[204]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}